|
Chongqing Sintaho Pharmaceutical Co., Ltd.
|
Sintaho Pharmaceutical Ltd was established in the year of 2016 and headquartered in Chongqing China, with a grand vison of being the most trusted partner to pharmaceutical companies worldwide. We have a clear focus on developing and manufacturing highly potent and cytotoxic Active Pharmaceutical Ingredients (APIs) and CDMO services. |
Send Inquiry
|
|
Changzhou Comwin Fine Chemicals Co., Ltd.
|
Bortezomib is used to treat multiple myeloma and mantle cell lymphoma.
Before taking this medicine
You should not be treated with bortezomib if you are allergic to bortezomib, mannitol, or boron.
Tell your doctor if you have ever had:
-
nerve problems such as numbness, tingling, or burning pain;
-
diabetes;
-
liver disease;
-
kidney disease, or if you are on dialysis;
-
a low level of platelets or white or red blood cells;
-
heart disease, congestive heart failure;
-
lung disease or breathing problems;
-
herpes or shingles (herpes zoster);
-
high or low blood pressure; or
-
if you are dehydrated.
You may need to have a negative pregnancy test before starting this treatment.
Bortezomib can harm an unborn baby or cause birth defects if the mother or the father is using this medicine.
-
If you are a woman, do not use bortezomib if you are pregnant. Use effective birth control to prevent pregnancy while you are using this medicine and for at least 7 months after your last dose.
-
If you are a man, use effective birth control if your sex partner is able to get pregnant. Keep using birth control for at least 4 months after your last dose.
-
Tell your doctor right away if a pregnancy occurs while either the mother or the father is using bortezomib.
This medicine may affect fertility (ability to have children) in both men and women. However, it is important to use birth control to prevent pregnancy because bortezomib may harm the baby if a pregnancy does occur.
You should not breastfeed while using this medicine and for at least 2 months after your last dose. |
Send Inquiry
|
Pharma Sources Insight January 2025
